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Abstract Matrix metalloproteinases (MMPs) play an
important role in modeling of the extracellular matrix.
There is increasing evidence that these proteases are
important in neurite elongation and axonal guidance during
development in the central nervous system and retina.
Moreover, they are also expressed after acute injury and
can be the key mediators of pathogenesis. However, the
role of MMPs in the inner ear is largely unknown. Our
group recently demonstrated that general inhibition of
MMPs resulted in auditory hair cell loss in vitro. In the
present study, we investigated the role of MMPs in inner
ear spiral ganglion neuron (SGN) survival, neuritogenesis
and neurite extension by blocking MMPs known to be
involved in axonal guidance, neurite elongation, and
apoptosis in other neuronal systems. Spiral ganglion (SG)
explants from 5-day-old Wistar rats were treated with
different concentrations of the general MMP inhibitor
GM6001, a specific MMP-2 inhibitor, and a specific MMP-
9 inhibitor, in vitro. The general inhibitor of MMPs and the
specific inhibition of MMP-2 significantly reduced both the
number of neurites that extended from SG explants, as well
as the length of individual neurites. However, neither the
general inhibitor of MMPs nor the specific inhibition of
MMP-2 influenced SGN survival. Inhibition of MMP-9 had
no influence on SGNs. The data suggest that MMPs, and
more specifically MMP-2, influence the growth of devel-
oping afferent neurites in the mammalian inner ear in vivo.
Keywords Extracellular matrix  Inner ear  Matrix
metalloproteinase  Spiral ganglion neurons
Introduction
Matrix metalloproteinases (MMPs) are zinc-dependent
proteases that play an important role in modeling the
extracellular matrix (ECM), which proves structural and
biochemical support to the cells that they surround. In the
brain, the ECM occupies the space between neural and
glial cells and mediates various structural and functional
interactions between the cells (Sorokin 2010; Faissner et al.
2010). During development, the ECM plays a crucial role
in proliferation, migration, and differentiation of neural
cells. The ECM of the nervous system is modulated by
various proteinases secreted by neurons and glia (Page-
McCaw et al. 2007; Yong 2005). Among these are the
MMPs, which can be divided into four main subgroups
based on their targets and structural domains: collagenases,
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gelatinases, stromelysins, and membrane-type MMPs
(Rosenberg 2009). Currently, the two secreted gelatinases,
MMP-2 and MMP-9, are the most frequently investigated
MMPs in the central nervous system because they are
detected relatively easily (Fujioka et al. 2012).
There is increasing evidence that MMPs are important in
neurite elongation and axonal guidance during develop-
ment, since the ECM is typically remodeled as axons
elongate between cells. In vivo experiments on Xenopus
using the general MMP inhibitor GM6001 demonstrated
the importance of MMPs for axon guidance and extension
in the developing visual system (Webber et al. 2002).
Moreover, MMP-9 deficiency affects axonal outgrowth,
migration, and apoptosis in the developing murine cere-
bellum (Vaillant et al. 2003). MMPs not only play a crucial
role in development, but are also expressed acutely after
injury and are the key mediators of pathogenesis (Zhang
et al. 2011; Agrawal et al. 2008). Studies in cerebral
hypoxia/ischemia in rodents and non-human primates
showed an elevation in MMP-2 expression 2 h after
reperfusion (Chang et al. 2003; Yang et al. 2007). A
marked increase in MMP-9 expression between 24 and
48 h after reperfusion provides a molecular basis for both
the transient and long-term alterations that occur in the
blood–brain barrier due to MMPs in reperfusion injury
(Yang et al. 2007). In human ischemic strokes, active
MMP-2 is increased on days 2–5 compared with active
MMP-9, which can remain elevated for months after the
ischemic episode (Clark et al. 1997). Furthermore, studies
have shown that ischemic-induced retinal ganglion cell loss
in mice correlates with an up-regulation of MMP-9. In
addition, MMP-9 knockout mice, and mice treated with
MMP synthetic inhibitor, are resistant to ischemic-induced
retinal ganglion cell loss, indicating that MMP-9 plays a
causative role (Chintala et al. 2002; Zhang and Chintala
2004).
As in the brain, the cells of the mammalian cochlea are
embedded in a highly organized ECM. Several ECM
molecules are positioned along the path of the developing
afferent dendrites that link the cell bodies of spiral ganglion
neurons (SGNs) to their target cells in the sensory epithe-
lium (Woolf et al. 1992; Whitlon et al. 1999a, b). More-
over, the neurites of SGNs have been shown to respond
strongly to ECM molecules in vitro. For example, both
laminin and fibronectin strongly stimulate the growth of
neurites when presented as a uniform surface (Aletsee et al.
2002; Evans et al. 2007). Interestingly, neurites avoid ter-
minating on stripes of fibronectin when given a choice with
a neutral molecule (poly-L-lysine), and either avoid or are
attracted to laminin stripes depending upon concentration
(Evans et al. 2007). It, therefore, seems reasonable that
MMPs would be capable of modulating the responses of
spiral ganglion (SG) neurites.
In contrast to the central nervous system and the retina,
the role of MMPs in the inner ear is largely unknown.
MMP-2 is strongly expressed in the embryonic inner ear,
along the pathway between the SG and the hair cells (HCs)
(Genepaint 2013). Inactivating the Mpv17 gene in mice,
which encodes for a peroxisomal protein, induced a strong
increase in MMP-2 expression in the inner ear (Reuter
et al. 1998). These mice developed a degeneration of var-
ious inner ear structures including the loss of SGNs and
degeneration of the organ of Corti as well as hearing loss.
Cochlear ablation experiments in rats indicate that MMP-9
tends to be associated with neuropil reorganization related
to fiber and terminal degeneration, whereas MMP-2 is
predominantly involved in aiding reinnervation and syna-
ptogenesis (Fredrich and Illing 2011). Interestingly, mice
with hyperhomocysteinemia display an increase in
cochlear expression of MMP-2 and MMP-9 (Kundu et al.
2009). However, hearing tests in these mice have not been
performed. We previously found that inhibition of MMP
activity resulted in auditory HC loss in vitro (Setz et al.
2011). However, the effect of MMP inhibition has not been
investigated in SGNs.
The aim of the present study was to evaluate the effect
of MMP inhibitor on SGNs in vitro. We used MMP
inhibitors known to block MMPs involved in axonal
guidance, neurite elongation, and apoptosis in other neu-
ronal systems. The effect on SG neuronal survival, neu-
ritogenesis, and neurite elongation of the general MMP
inhibitor GM6001, as well as specific MMP-2 and MMP-9
inhibitors was analyzed.
Materials and Methods
Preparation of Tissue Culture Plates
To prepare uniformly coated 24-well cell culture plates
(Costar, Corning Inc, Acton, MA, USA), wells were filled
with 300 ll of 5 lg/ml poly-L-lysine (PLL) (Sigma-
Aldrich, St. Louis, USA) in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco by Invitrogen, Carlsbad, USA)
and incubated at 37 C for 1 h. The wells were then
washed twice with phosphate buffered saline (PBS). The
prepared wells were then filled with 170 ll of primary
attachment medium, containing DMEM (Gibco), 10 %
fetal bovine serum (Sigma-Aldrich), 25 mM HEPES buffer
(Gibco) ,and 300 U/ml penicillin (Sigma-Aldrich).
SG Dissection
All animal procedures were carried out according to an
approved animal research protocol (Kantonales Veteri-
naeramt, Basel, Switzerland and the IACUC of the San
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Diego VA Medical Center, USA). Neonatal 5-day-old
Wistar rats (Harlan, Indianapolis, USA) were euthanized.
The temporal bones were removed and further dissected
similar to the method described by Van de Water and
Ruben (1971). Briefly, the cochlear capsule was opened,
and the membranous labyrinth was removed from the
modiolus. The spiral lamina containing the SG was care-
fully separated from the modiolus and transferred imme-
diately into primary cell culture medium, where it was then
cut into equal portions of 300–500 lm before being
transferred to the prepared culture plates. Each explant was
cultured in a separate culture well.
Cell Culture
The explants were first incubated for 24 h at 37o C in
primary attachment medium, and the culture medium was
subsequently changed to serum-free maintenance medium
[DMEM (Gibco), 25 mM Hepes Buffer (Gibco), 6 mg/ml
glucose (Gibco), 300 U/ml penicillin (Sigma-Aldrich), and
30 ll/ml N2-supplement (Gibco)]. Maintenance medium
was supplemented with 10 ng/ml of recombinant BDNF
for trophic support of SGN survival and optimization of
neurite outgrowth (R&D Systems, Minneapolis, MN,
USA). Cultures were kept in a humidified incubator at 5 %
CO2 and 37 C for 72 h.
Experimental cultures received various concentrations
of MMP inhibitors. This included 10 or 50 lM of the
general MMP inhibitor GM6001 (Calbiochem). GM6001 is
a potent, cell-permeable, broad-spectrum hydroxamic acid
inhibitor of MMPs (Ki = 400 pM for MMP-1, 500 pM for
MMP-2, 27 nM for MMP-3, 100 pM for MMP-8, and
200 pM for MMP-9). An MMP-2 inhibitor (Calbiochem)
was used at 5, 20, or 50 lM. This MMP-2 inhibitor is a
cell-permeable, potent inhibitor of MMP-2 that acts in a
dose-dependent manner (Ki = 1.7 lM). An MMP-9
inhibitor was used at 5, 50, or 500 nM. This MMP-9
inhibitor is a cell-permeable, potent, selective, and
reversible MMP-9 inhibitor (IC50 = 5 nM), which inhibits
MMP-1 (IC50 = 1.05 lM) and MMP-13 (IC50 = 113 nM)
only at much higher concentrations. Detailed information
about the selectivity of the inhibitors used is available at
the suppliers website (Calbiochem, www.calbiochem.com/
inhibitors/MMP).
A GM6001 negative control (GM6001NC; N-t-butoxy-
carbonyl-L-leucyl-L-tryptophan methylamide) (Calbio-
chem), a closely related compound without MMP inhibitor
activity, was also prepared and used at a concentration of
50 lM (Webber et al. 2002). Additional control media for
the MMP-2 inhibitor and MMP-9 inhibitor experiments
contained dimethyl sulfoxide (DMSO) alone (Sigma-
Aldrich), since MMP inhibitors were solubilized in DMSO
(Sigma-Aldrich). The concentration of DMSO (Sigma-
Aldrich) used in controls was the same as the highest
concentration of the specific inhibitor used.
Immunohistochemistry
After fixation with 4 % paraformaldehyde for 20 min at
room temperature (RT) and two washes with PBS (Gibco),
the explants were permeabilized with 5 % triton X-100
(Sigma-Aldrich) for 10 min, washed twice with PBS, and
blocked for non-specific antibody binding with 5 % donkey
serum (Sigma-Aldrich). Neurites were labeled for neuro-
filament using a mouse polyclonal 200 kDa anti-neurofil-
ament primary antibody (1:400; Sigma-Aldrich). After
primary antibody incubation overnight at 4 C, followed by
two PBS washes, the neurites were visualized by 2.5 h of
incubation with fluorescein isothiocyanate (FITC)-conju-
gated secondary antibodies (1:100; Jackson Immunore-
search, West Grove, PA, USA) against mouse antibody.
Specificity of staining was confirmed by a series of nega-
tive control staining without primary antibodies.
Quantification of Neuronal Survival
To assess effects on neuronal survival, half turn SG
explants were cultured as above for 72 h, except that the
explants were grown on glass cover slips. The explants
were fixed as above, treated with 0.5 % peroxide in
methanol to block endogenous peroxidases, reacted with a
mouse monoclonal antibody IgG against rat neurofilament
200 (Sigma- Aldrich), followed by a biotinylated second-
ary anti-mouse IgG, and developed by an avidin and DAB
procedure (Vector Laboratories, Burlingame, CA, USA).
The tissue was cleared with citrosol (Fischer Scientific,
Waltham, MA, USA) to allow the visualization of the cell
somas for the evaluation of neuronal survival. 36 SG
explants were studied for each condition.
Data Analysis
Digital images for immunohistochemistry were obtained
on a fluorescence microscope (Olympus IX71, Center
Valley, PA, USA) and photographed with an AxioCam
(Zeiss, San Diego, USA). Digital images for the quantifi-
cation of neuronal survival were obtained on an inverted
microscope (Olympus FSX100, Center Valley, PA, USA).
For publication in this manuscript, images were optimized
to achieve uniform brightness and contrast using Adobe
Photoshop (Adobe Systems Inc., San Jose, CA, USA).
Neurite outgrowth from the SG was evaluated by mea-
suring the number and lengths of the processes. Growth of
supporting cells was evaluated by measuring the area of the
skirt surrounding the SGN. Images of the immunostained
cultures were analyzed by using ImageJ software (NIH,
Cell Mol Neurobiol (2014) 34:1011–1021 1013
123
Bethesda, MD, USA). Each neurite was traced, and number
of neurites, average lengths of neurites, and area of the
supporting cells per explant were analyzed. Neuronal sur-
vival was analyzed by evaluating the number of neurons
per 100 lm. Statistical analysis was performed using a
one-way analysis of variance (ANOVA) followed by
Tukey’s least-significant-difference post hoc test with
Bonferroni correction. Data presented in the text and fig-
ures are the means and standard deviations. Results were
considered to be significant when the likelihood for a type
1 error was less than 5 % (p \ 0.05). 20 SG explants were
studied for each condition.
RNA Extraction
6 SGNs of 5-day-old WS rat pups for each experimental
condition were cultured and treated with 500 nM MMP-9
inhibitor (Calbiochem) as described above for 3 h and
placed separately in RNAlater (Qiagen, Hombrechtikon,
Switzerland). RNA isolation was performed using the
RNAeasy Minikit (Qiagen, Switzerland) including DNase
treatment according to the supplier’s instructions. An
Ultra-Turrax T8 homogenizer (IKA- Werke, Staufen,
Germany) was used to homogenize the tissues. The quan-
tity and quality of the isolated RNA were determined with
NanoDrop ND 1000 (NanoDrop Technologies, DE, USA).
The 260/280 nm ratio of all our samples was between 1.8
and 2.1.
Real-Time PCR
Total RNA (500 ng) was reverse transcribed into cDNA
with the first strand cDNA synthesis kit (Roche Applied
Biosciences, Rotkreuz, Switzerland) according to the sup-
plier’s instructions. The reaction took place in an ABI
Prism 7900HT Sequence Detection System (Applied Bio-
systems, Foster City, USA) using a Fast Start Universal
SYBR Green Master (Rox) (Roche Applied Biosciences,
Rotkreuz, Switzerland). The primer sequences were MMP-
9 reverse 50-GGTCAGGTT-TAGAGCCACGA-30 (Mi-
crosynth, St. Gallen, Switzerland). Each reaction contained
300 nM of primer. The cycling parameters were 10 min at
95 C, then 40 cycles of 15 s at 95 C, and 60 s at 60 C.
We calculated the relative quantities of specifically
amplified cDNA with the comparative threshold cycle
method. GAPDH acted as an endogenous reference. Rel-
ative expression of MMP-9 mRNA was compared to
DMSO control. No-template and no-reverse-transcription
controls served as negative controls and excluded DNA
contamination. All experiments were repeated three times
in triplicate.
Results
General Inhibition of MMP Activity Results
in Decreased SG Neurite Number
Treatment of neonatal SG explants with the general MMP
inhibitor GM6001 (10 or 50 lM, respectively) decreased
the number of neurites per SG explant compared to the
negative control (50 lM GM6001NC) (Fig. 1b, ANOVA,
p \ 0.05 for both conditions). Figure 1a shows a repre-
sentative image of SG explants treated with the different
concentrations of the general MMP inhibitor GM6001
compared to 50 lM GM6001 negative control (NC).
General Inhibition of MMP Activity Results
in Decreased Length of SG Neurites
The general MMP inhibitor GM6001 (10 or 50 lM,
respectively) also significantly decreased the length of SG
neurites compared to the negative control (50 lM
GM6001NC) (Fig. 1c, ANOVA, p \ 0.05 for both condi-
tions). Figure 1a shows a representative image of SG
explants treated with the different concentrations of the
general MMP inhibitor GM6001 versus 50 lM GM6001NC.
General Inhibition of MMP Activity Results
in Decreased Area of Supporting Cells
The general MMP inhibitor GM6001 (10 lM) also sig-
nificantly decreased the area of non-neuronal cells, which
we have previously identified as fibroblasts and Schwann
cells (Aletsee et al. 2001; Brors et al. 2002), growing
around the explant, as compared to the negative control
(50 lM GM6001NC) (Fig. 4b, ANOVA, p \ 0.05).
Figure 4a shows a representative image of SG explants
treated with the general MMP inhibitor GM6001 versus
GM6001NC.
Specific Inhibition of MMP 2 Activity Results
in Decreased SG Neurite Number in a Dose-Dependent
Manner
Treatment of neonatal SG explants with a MMP-2 inhibitor
(5, 20, or 50 lM, respectively) significantly decreased the
number of neurites per SG explant compared to DMSO
control in a dose-dependent manner (Fig. 3a, ANOVA,
p \ 0.05 for all conditions). Figure 2 shows a representa-
tive image of SG explants treated with the different con-
centrations of the MMP-2 inhibitor compared to a DMSO
control.
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Specific Inhibition of MMP-2 Activity Results
in Decreased Length of SG Neurites in a Dose-
Dependent Manner
Treatment of neonatal SG explants with a MMP-2 inhibitor
(5, 20, or 50 lM, respectively) also decreased the length of
SG neurites compared to DMSO control (Fig. 3b, ANOVA,
p \ 0.05 for all conditions). Figure 2 shows a representative
image of SG explants treated with the different concentra-
tions of the MMP-2 inhibitor compared to DMSO control.
Specific Inhibition of MMP-2 Activity Results
in Decreased Area of Supporting Cells
The specific MMP-2 inhibitor (20 lM) also significantly
decreased the area of non-neuronal cells around the SGN
compared to the DMSO control (Fig. 4d, ANOVA,
p \ 0.05). Figure 4c shows a representative image of SG
explants treated with the specific MMP-2 inhibitor versus
DMSO control.
Specific Inhibition of MMP-9 Activity Does
not Influence Number or Length of SG Neurites
Treatment of neonatal SG explants with a MMP-9 inhibitor
(5, 50, or 500 nM, respectively) had no effect on either the
number of neurites per SG explant (Fig. 3a, ANOVA,
p [ 0.05 for all conditions) or the length of SG neurites
(Fig. 3b, ANOVA, p [ 0.05 for all conditions) when
compared to controls. Figure 2 shows a representative
image of SG explants treated with the different concen-
trations of the MMP-9 inhibitor versus the DMSO control.
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Fig. 1 a Representative SG explants stained with anti-200 kDa
neurofilament antibody after treatment with 50 lM GM6001 negative
control, 10 lM GM6001, and 50 lM GM6001. Scale bar 300 lm.
b Average number of SG neurites observed on SG explants. The
number of neurites observed with 50 lM GM6001 negative control is
compared to that seen with two different concentrations of the general
MMP inhibitor GM6001. GM6001-treated samples were significantly
different from control in both concentrations used. c Average length
of SG neurites observed on SG explants. The length of neurites
observed in control samples (50 lM GM6001 negative control) are
compared to that seen with two different concentrations of the general
MMP inhibitor GM6001. GM6001-treated samples were significantly
different from control in both concentrations used. Asterisks denote
statistical difference compared to control. Data are represented as
mean ? SD. N = 20 for each experimental condition
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MMP-9 mRNA relative expression of SG explants
treated with the highest concentration used in the experi-
ments compared to DMSO control was analyzed. Treat-
ment with 500 nM MMP-9 inhibitor increased MMP-9
mRNA expression compared to DMSO control (Fig. 5,
ANOVA, p \ 0.05). The change in mRNA expression
served as positive control, since no effect of MMP-9
inhibitor treatment on SGN neurites was observed.
General Inhibition of MMP Activity and Specific
Inhibition of MMP-2 Activity Does not Influence
Neuronal Survival
The decreased number of neurites extending from SG
explants could reflect the altered survival and/or neurito-
genesis of SGNs. To assess this, we evaluated the survival
of SGN cell bodies within explants treated with dosages of
the general MMP inhibitor GM6001 (10 lM) or the spe-
cific MMP-2 inhibitor (20 lM) that altered the neurite
number. However, neither treatment influenced SG neu-
ronal survival when compared to controls. (Figure 6b, c,
ANOVA, p [ 0.05 for both conditions). Figure 6a shows
the representative images of SG explants treated with
10 lM of the general MMP inhibitor GM6001 compared to
10 lM GM6001 negative control and SG explants treated
with 20 lM of a specific MMP-2 inhibitor compared to
DMSO control.
Discussion
At present, information about the function of MMPs in the
inner ear is limited. Hu et al. (2012) showed that MMPs
and their related genes participate in the regulation of
MMP-9 inhibitor 5 nM MMP-9 inhibitor 50 nM MMP-9 inhibitor 500 nM
MMP-2 inhibitor 5 µM MMP-2 inhibitor 20 µM MMP-2 inhibitor 50 µM
DMSO control
Fig. 2 Representative SG explants stained with anti-200 kDa neuro-
filament antibody after treatment with DMSO only, 5 lM MMP-2
inhibitor, 20 lM MMP-2 inhibitor, 50 lM MMP-2 inhibitor, 5 nM
MMP-9 inhibitor, 50 nM MMP-9 inhibitor, and 500 nM MMP-9
inhibitor. Scale bar 300 lm
1016 Cell Mol Neurobiol (2014) 34:1011–1021
123
cochlear response to acoustic overstimulation. The authors
suggested that the modulation of MMP activity can serve
as a novel therapeutic target for the reduction of noise-
induced cochlear damage. However, Hu et al. (2012)
focused on the sensory epithelium of the cochlea and not
on SGNs. Recently, our group demonstrated that general
inhibition of MMPs resulted in auditory HC loss in vitro
(Setz et al. 2011). The data of the present study indicates
that MMP inhibition not only affects the auditory HCs, but
also has a negative influence on SGNs. These findings
suggest that MMPs play an important role in regulating the
homeostasis of the ECM in the inner ear. Interestingly, the
effect of the general inhibitor GM6001 on SGNs was
similar to the specific MMP-2 inhibitor, while inhibition of
MMP-9 had no effect. This indicates that the effects on
SGNs can be attributed primarily to MMP-2 inhibition,
although the possibility that additional MMPs may also
participate cannot be excluded.
SG explants treated with the general MMP inhibitor
GM6001 and the specific MMP-2 inhibitor showed a sig-
nificant reduction in the number of neurites per SG explant.
In order to clarify whether the reduction in number of
neurites per SG explants reflects the failure of neurite ini-
tiation or diminished neuronal survival, we evaluated SG
neuronal survival by visualization of the cell soma of the
SGNs. General MMP inhibitor GM6001 and specific
MMP-2 inhibitor treatment did not influence SG neuronal
survival. Therefore, the reduction in number of neurites per
SG explant represents neuritogenesis and not SG neuronal
survival.
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Fig. 3 a Average number of SG neurites observed on SG explants.
The number of neurites observed on control (DMSO only) is
compared to those seen with three different concentrations of the
MMP-2 and MMP-9 inhibitor. MMP-2 inhibitor-treated samples were
significantly different from control at the two highest concentrations
used. MMP-9 inhibitor treatment had no influence on the average
number of SG neurites observed on SG explants. Asterisks denote
statistical difference compared to control. Data are represented as
mean ? SD. N = 20 for each experimental condition. b The average
length of SG neurites observed on SG explants. The length of neurites
observed in control samples (DMSO only) are compared to those seen
at the three different concentrations of the MMP-2 and MMP-9
inhibitor. MMP-2 inhibitor-treated samples were significantly differ-
ent from control at the two highest concentrations. MMP-9 inhibitor
treatment had no influence on neurite length. Asterisks denote
statistical difference compared to control. Data are represented as
mean ? SD. N = 20 for each experimental condition
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This difference in response to MMP-2 and MMP-9
inhibition could be related to the substrate specificities of
the two MMPs. MMP-2 actively degrades not only colla-
gens, but also fibronectin and laminin. In contrast, MMP-9
degrades collagens and fibronectin but not laminin. As
noted above, we have previously shown that laminin
increases both SG neurite number and length in vitro
(Aletsee et al. 2002). If MMP-2 exposes laminin epitopes
deposited on the growth surface by cells of the explant, it
could increase signaling from this ECM, while MMP-9
would not be expected to do so. Cleavage of laminins by
MMP-2 has been shown to enhance the laminin responses
of other cell types (Giannelli et al. 1997). Since we also
found that a uniform fibronectin surface increases SG
neurite number and length (Evans et al. 2007), the lack of
effect of MMP-9 may imply that FN is less important than
laminin SG neurite growth in our system, or that processing
by MMPs is not required for the neurotropic effects of
fibronectin.
However, it should be noted that with the exception of
MMP-2, which is constitutively expressed in various
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Fig. 4 a Representative SG explants stained with anti-200 kDa
neurofilament antibody after treatment with 50 lM GM6001 negative
control and 10 lM GM6001. c Representative SG explants stained
with anti-200 kDa neurofilament antibody after treatment with 20 lM
MMP-2 inhibitor and DMSO control. Scale bar 300 lm. b Average
area of supporting cells observed around SG explants. GM6001
treatment resulted in significantly smaller area of supporting cells
around the SG explant compared to GM6001 negative control.
d Average area of supporting cells observed around SG explants.
MMP-2 inhibitor treatment resulted in significantly smaller area of
supporting cells around the SG explant compared to DMSO negative
control. Asterisks denote statistical difference compared to control.
Data are represented as mean ? SD. N = 20 for each experimental
condition
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Fig. 5 MMP-9 mRNA relative expression in SG explants after
treatment with and without 500 nM MMP-9 inhibitor. MMP-9 mRNA
relative expression in control SG explants (DMSO control) has a
value of 1 and was used as a comparison parameter. Expression was
measured by quantitative real-time PCR with GAPDH as an
endogenous control. Histogram and bars represent mean ? SD.
*p \ 0.05 versus DMSO control. The experiment was repeated three
times in triplicates. N = 6 for each experimental condition
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tissues, MMPs are induced in response to exogenous sig-
nals such as growth factors and cytokines (Chintala 2006).
A possible explanation of our findings is that under non-
pathological conditions, the level of active MMPs other
than MMP-2 is very low and, therefore, their inhibition
does not influence the SGNs in vitro.
Our findings are in line with a prior study showing that
homeostasis of MMP-2 is important in the inner ear. Reuter
et al. (1998) demonstrated that a strong increase in MMP-2
expression in the inner ear causes degeneration of various
inner ear structures, including a loss of SGNs and degen-
eration of the organ of Corti along with hearing loss. Our
data indicates that a basal level of MMP-2 activity is
required for normal SG neurite outgrowth and survival.
Reuter et al. (1998) and our results suggest that homeo-
stasis of MMP-2 must be tightly regulated in the inner ear.
How can the negative effect of both MMP-2 inhibition and
MMP-2 overexpression on SGNs be explained? A study of
endothelial cells showed that the mitogen-activated kinase
(MAPK) and jun N-terminal kinase (JNK) regulate MMP-2
mRNA expression, while phosphatidylinositol-3-kinase
(PI3K) regulates protein levels of MMP-2 (Ispanovic and
Haas 2006). We and others have demonstrated that PI3K-
Akt signaling mediates the formation of neurites (Mullen
et al. 2012; Lallemend et al. 2005; Hansen et al. 2001).
However, we recently showed that Rac/cdc42/JNK sig-
naling reduces the formation of neurites (Mullen et al.
2012). Inhibition and overexpression of MMP-2 may alter
this balance between competing intracellular signaling
pathways. While this hypothesis is perhaps too complex to
be attractive without additional supporting data, it is at
least consistent with our observations. Further studies will
be needed to clarify this issue.
In our experiments, we used organotypic explants from
the cochlear SG. Besides neurons, the explants contained
supporting cells, including fibroblasts and Schwann cells,
which reside between the neurons in vivo. Both cells are
known to provide guidance cues to advancing neurites and
growth cones, and, therefore, might have influenced the
observed reduction in neuritogenesis and length of neurites
in our experiments. SG explants treated with the general
MMP inhibitor GM6001 and the specific MMP-2 inhibitor
showed not only decreased in number of neurites per SG
explant and reduction in length of neurites, but also a
significant decrease of the area of the supporting cells
surrounding the SG explant. The inhibition of non-neuronal
cell growth was somewhat less than the inhibition of
neurite length. However, this finding suggests that the
reduction of SG neurite elongation due to MMP inhibitors
may be mediated, at least in part, via Schwann cells or
fibroblasts. However, the possibility of directly mediated
effects must still be considered. For example, MMP-2 can
enhance neurite outgrowth directly by cleaving and inac-
tivating the neurite growth inhibitor CD44 (Zhang et al.
2007). CD44 is present in the developing cochlea, includ-
ing in the organ of Corti (Hertzano et al. 2010).
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Fig. 6 Effects of MMP inhibition on neuronal survival from SG
explants. a Representative SG explants after treatment with 10 lM
GM6001 negative control, 10 lM GM6001, DMSO control, and
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treatment showed a difference in SG neuron survival compared to
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It should be noted that we could not distinguish between
the dendrites and axons of SGNs, since we have not found
markers that distinguish between the two in explants.
Similarly, we could not distinguish between type I and type
II SGN neurites, since peripherin labeling in the rat does
not distinguish between these two classes of neurons, due
to the up-regulation of peripherin in Type I neurons in vitro
(Lallemend et al. 2007). However, since 95 % of SGNs are
type I cells, it seems likely that this class of neuron dom-
inates our results. In our study, we used 5-day-old rat
SGNs. Onset of hearing in the rat cochlea approximately
occurs on postnatal day 10 (Henley et al. 1989; Rybak et al.
1992). Prehearing neurons were studied, since older neu-
rons are more difficult to culture and neurite development
is ongoing at this age (Ernfors et al. 1995; Echteler and
Nofsinger 2000).
In summary, we have shown that MMP-2 can modulate
neonatal SG neuritogenesis and neurite elongation in vitro,
suggesting that this enzyme may play a role in the devel-
opment of the cochlear innervation.
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